Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Next-Generation Sequencing in Lung Cancer

February 7th 2014

Determining When to Administer Maintenance Therapy in NSCLC

February 7th 2014

Maintenance Therapy in Non-Small Cell Lung Cancer

February 7th 2014

Optimizing Maintenance Therapy in NSCLC

February 7th 2014

Adjuvant EGFR Inhibition in Patients With NSCLC

February 7th 2014

Next-Generation Targeted Therapies in NSCLC

February 7th 2014

Development of ALK Inhibitors in Advanced NSCLC

February 7th 2014

Second-Generation ALK Inhibitors in NSCLC

February 7th 2014

Current Status of Immunotherapy in NSCLC

February 7th 2014

Immune Checkpoint Inhibitor Combinations in NSCLC

February 7th 2014

Checkpoint Inhibitor Related Pseudoprogression in NSCLC

February 7th 2014

Introduction: Checkpoint Inhibition in NSCLC

February 7th 2014

Dr. Peeters on KRAS/NRAS Mutations in mCRC

February 6th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of mCRC

Pancreatic Cancer Starkly Illustrates Challenges of Developing Targeted Therapies

February 4th 2014

A recent study determined that it would take 6.7 years on average to enroll enough patients with pancreatic cancer for the trials that opened in 2011-a tall order considering that the 5-year relative survival rate for those diagnosed with pancreatic ductal adenocarcinoma is only 6%.

Targeting CD30: Research Focuses on Potential for Expanded Role in Hematologic Malignancies

January 24th 2014

The cytokine receptor CD30 was identified as an attractive anticancer target more than 30 years ago

OncLive Adds Winship Cancer Institute of Emory University to its Strategic Alliance Partnership Program

January 22nd 2014

OncLive will work with Georgia's only NCI-designated cancer center to support its efforts to conduct innovative, multidisciplinary research and translate that knowledge into excellent patient care.

Dr. Fakih on RAS Mutations in Colon Cancer

January 22nd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses extended RAS mutations in colon cancer.

Conclusion: Future Direction of Breast Cancer Treatment

January 22nd 2014

Preventing Skeletal-Related Events in Breast Cancer

January 22nd 2014

Chemotherapeutics in Metastatic Breast Cancer

January 22nd 2014